Home › Compare › PAEGF vs ABBV
PAEGF yields 200000.00% · ABBV yields 3.06%● Live data
📍 PAEGF pulled ahead of the other in Year 1
Combined, PAEGF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PAEGF + ABBV for your $10,000?
Peace Arch Entertainment Group Inc. produces, acquires, and distributes feature films, television, and home entertainment content worldwide. It operates in three segments: Motion Picture, Television, and Home Entertainment. The Motion Picture segment produces feature films, which are intended for DVD or television premieres, as well as for worldwide theatrical release; licenses distribution rights of productions to sub-distributors; and distributes catalogues. The Television segment licenses television films, series of episodes, documentaries, and other programming to broadcasters, cable and satellite television providers, and home entertainment distributors. It also provides made-for-television movies and mini-series. The Home Entertainment segment distributes DVDs and ancillary merchandise to retailers in Canada and the United States. This segment also distributes sell-through and rental films of various genres, such as children's and family, special interest, and live action feature films. The company was formerly known as Vidatron Entertainment Group Inc. and changed its name to Peace Arch Entertainment Group Inc. in July 1999. Peace Arch Entertainment Group Inc. was founded in 1986 and is based in Toronto, Canada.
Full PAEGF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.